Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Established diagnosis of ulcerative colitis (UC), based on clinical history, exclusion of infectious causes, and characteristic endoscopic and histologic findings.~2. Active UC with disease confirmed by endoscopy findings and confirmed by central reader.~3. A modified Mayo Score 4-10, and with a centrally read endoscopy score activity of ≥ 2 points.~4. Mesalamine (5-ASA) refractory.~Exclusion Criteria:~1. Diagnosis of Crohn's disease, indeterminate colitis, ischemic colitis, radiation colitis, microscopic colitis (i.e., collagenous colitis and lymphocytic colitis), diverticular disease associated colitis,~2. Toxic megacolon or fulminant colitis,~3. Prior colon resection,~4. Evidence of infectious colitis (e.g., pathogenic bacteria or Clostridium difficile infection) at screening,~5. Known celiac disease~6. Other inflammatory or bleeding disorders of the colon and intestine, or diseases what may cause diarrhea or gastrointestinal bleeding~7. History or presence of ischemic heart disease, myocardial infarction, peripheral arterial disease, ischemic stroke, or transient ischemic attack,~8. Subjects with known hypersensitivity to soy,~9. Treatment with methotrexate, azathioprine, 6-mercaptopurine TNF-alpha-antagonists, vedolizumab or certolizumab pegol, tacrolimus, or anti-integrin therapy within last 8 weeks prior to screening,~10. Treatment with any (topical or systemic) corticosteroid formulation for the treatment of IBD within last 7 days prior to endoscopy,~11. Treatment with other investigational drug within last 8 weeks prior to screening,

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- LT-02 (Type: EXPERIMENTAL): 1.6 g PC in LT-02 BID
- LT-02 Placebo (Type: PLACEBO_COMPARATOR): 0 g PC in LT-02 Placebo BID

Based on this trial design, predict the completion outcome and termination type (if applicable).